ArticleOpen access Macedonian journal of medical sciences2018
Micro - Focused Phototherapy Associated To Janus Kinase Inhibitor: A Promising Valid Therapeutic Option for Patients with Localized Vitiligo.
Article in Open access Macedonian journal of medical sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and Safety of Janus Kinase Inhibitors in Patients with Vitiligo: A Systematic Review and Meta-Analysis.Clinical pharmacology and therapeutics · 2025Pooled it
- A systematic review of case series and clinical trials investigating systemic oral or injectable therapies for the treatment of vitiligo.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Pooled it
- A Review of Randomized Controlled Trials for Vitiligo Therapies Published Between 2013 and 2023.Cureus · 2026Review
- Efficacy and Safety of Small Molecule Inhibitor Therapies for Vitiligo: A Systematic Review.Health science reports · 2026Review
- Tofacitinib as a Promising Therapeutic Option for Vitiligo: A Systematic Review.Clinical, cosmetic and investigational dermatology · 2026Review
- Hotspots and Emerging Trends in JAK Inhibitor Therapy for Vitiligo: A Bibliometric Analysis (2015-2025).Journal of inflammation research · 2026Article
- Laser-Assisted Lipolysis: A Promising Alternative to Traditional Liposuction.Aesthetic plastic surgery · 2025Review
- Efficacy and Safety of JAK Inhibitors in the Management of Vitiligo: A Systematic Review and Meta-analysis.Dermatology and therapy · 2025Review
- Vitiligo: Pathogenesis and New and Emerging Treatments.International journal of molecular sciences · 2023Review
- Updates on Potential Therapeutic Approaches for Vitiligo: Janus Kinase Inhibitors and Biologics.Journal of clinical medicine · 2023Review
- Advances in vitiligo: Update on therapeutic targets.Frontiers in immunology · 2022Review
- The Promising Role of Chemokines in Vitiligo: From Oxidative Stress to the Autoimmune Response.Oxidative medicine and cellular longevity · 2022Review
- Role of Cytokines in Vitiligo: Pathogenesis and Possible Targets for Old and New Treatments.International journal of molecular sciences · 2021Review
- Vitiligo: What's old, what's new.Dermatology reports · 2021Article
- Successful Treatment of Vitiligo Vietnamese Patients with Vitilinex® Herbal Bio-Actives in Combination with Phototherapy.Open access Macedonian journal of medical sciences · 2019Article
- What Is New in Narrow-Band Ultraviolet-B Therapy for Vitiligo?Indian dermatology online journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVitiligo is an acquired pigmentary cutaneous disease, characterised by the progressive loss of melanocytes, resulting in hypopigmented skin areas which progressively become amelanotic. Classically, vitiligo treatments are unsatisfactory and challenging. Despite the continuous introduction of new therapies, phototherapy is still the mainstay for vitiligo repigmentation.
aimThe aim of this multicenter observational retrospective study was to evaluate the efficacy and safety of the nb - UVB micro - phototherapy (BIOSKIN EVOLUTION®), used alone or in associations with an oral Janus kinase inhibitor (Tofacitinib citrate), in the treatment of stable or active forms of localised vitiligo. MATERIAL AND
methodsFifty eight patients had been treated with n-UVB micro-photootherapy (Group A); 9 patients had been treated with phototherapy plus Tofacitinb citrate (Group B).
resultsAmong Group A, 42 patients (72%) obtained a re-pigmentation rate higher than 75%, with a medium value of 77%. 11 patients (19%) achieved a marked improvement of the clinical findings with a repigmentation rate between 50-75%; 4 patients (8%) showed a moderate response with a lesional repigmentation of 25-50%. Only one patient (1%) had a poor response to the phototherapeutic treatment.
conclusionNb - UVB micro-focused phototherapy is one of the most effective therapeutic options for vitiligo treatment. The association of micro-focused phototherapy to Tofacitinib citrate seems to provide better clinical results in term of repigmentation rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.